Continuing Education for Pharmacists: Staying Current on Generics

published : Jan, 17 2026

Continuing Education for Pharmacists: Staying Current on Generics

Pharmacists don’t just fill prescriptions-they make critical decisions every day about which medications are safe and effective for patients. And when it comes to generics, those decisions have real consequences. A wrong substitution can lead to treatment failure, adverse reactions, or even hospitalization. With over 90% of prescriptions filled with generic drugs in the U.S., staying current isn’t optional-it’s essential.

Why Generics Knowledge Is Non-Negotiable

Generics aren’t just cheaper versions of brand-name drugs. They’re legally required to match the original in strength, purity, quality, and performance. But here’s the catch: not all generics are created equal in practice. The FDA’s Orange Book lists over 1,200 therapeutic equivalence ratings, and those ratings change monthly. A pharmacist who doesn’t track these updates might think two generics are interchangeable when they’re not.

Take levothyroxine. Even tiny differences in bioavailability between brands can throw a hypothyroid patient into instability. In one case reported by a pharmacist on Reddit, switching from one generic to another without realizing they weren’t therapeutically equivalent caused a patient’s TSH levels to spike dangerously. That error was preventable-with proper education.

ACPE, the national accrediting body for pharmacy continuing education, found that 42.7% of all pharmacy malpractice claims between 2018 and 2021 involved errors related to generic substitution. That’s not a small number. It’s a systemic issue-and continuing education is the fix.

What You Need to Know About the FDA’s Rules

To approve a generic, the FDA requires manufacturers to prove bioequivalence: the generic must deliver the same amount of active ingredient into the bloodstream as the brand-name drug, within a range of 80% to 125%. That sounds precise, but it’s wide enough to matter clinically.

For drugs with a narrow therapeutic index-like warfarin, lithium, or phenytoin-that margin can be the difference between life and death. Pharmacists must know which generics are rated AB (therapeutically equivalent) and which are not. The Orange Book doesn’t just list drugs; it assigns ratings. AB1, AB2, BN, etc.-each means something different. Missing that distinction can lead to inappropriate substitutions.

And it’s not just about the FDA. The CREATES Act, passed in 2019, forces brand-name companies to provide samples to generic manufacturers so they can test for equivalence. But many generic developers still face delays or refusals. That means some generics enter the market without full testing, and pharmacists need to be aware of the risks.

State Laws Are a Maze

Every state has its own rules about when and how pharmacists can substitute generics. Texas requires pharmacists to notify prescribers before substituting narrow therapeutic index drugs. California mandates documentation of every substitution. New York requires you to submit proof of CE with your license renewal. Illinois doesn’t require submission unless audited-but you still need to keep records for five years.

And it’s getting more complicated. As of January 1, 2025, Illinois will require one hour of Cultural Competency training as part of CE. Other states now require training on opioid alternatives, biosimilars, or implicit bias. If you hold licenses in multiple states, you’re juggling different rules, deadlines, and topics. One CE course won’t cover it all.

Pharmacist explaining generic levothyroxine differences to a patient with TSH level visuals

Types of CE That Actually Work

Not all continuing education is created equal. Knowledge-based courses-where you watch a video and take a quiz-don’t stick. Pharmacists who take application-based courses, especially those using real case studies, report far fewer errors.

For example, a Pharmacist’s Letter module walked users through a case where a patient on generic levothyroxine had unexplained fatigue. The CE didn’t just explain bioequivalence-it asked: What’s your next step? Which lab values matter? How do you document your decision? That’s the kind of learning that changes behavior.

According to CE21 user reviews, application-based courses on generics score 4.7 out of 5. Knowledge-based ones? Only 3.2. The American Pharmacists Association found pharmacists who completed five or more hours of generics-specific CE annually made 37% fewer substitution errors. That’s not a coincidence-it’s proof that the right training works.

What’s Changing in 2025

ACPE announced new standards effective January 1, 2025: all generics-focused CE must now include content on biosimilars and FDA’s Risk Evaluation and Mitigation Strategies (REMS). Biosimilars aren’t traditional generics-they’re complex biologic drugs with no exact copy. Interchangeability isn’t automatic. Pharmacists need to understand the difference between biosimilar and interchangeable, and how to counsel patients.

Also, the FDA approved 983 new generic applications between January 2022 and June 2023-a 17% jump from the year before. That means new drugs, new generics, new substitution rules, and new risks. The pace of change is faster than most CE programs can keep up with.

Some providers are adapting. PocketPrep, a mobile CE platform, saw 45,000 pharmacist users in 2023, with 32% growth in generics content. CVS Health piloted just-in-time learning tools in their pharmacies-when a pharmacist selected a generic, a pop-up appeared with the latest Orange Book rating and substitution guidelines. Result? A 28% drop in errors.

Group of pharmacists studying biosimilars and state laws at a whiteboard in a hospital break room

How to Build Your Generics Learning Plan

You don’t have to wait for your state to mandate it. Here’s how to stay ahead:

  1. Track your state’s CE requirements. Know the hours, the mandatory topics, and the deadlines. Use your state board’s website-don’t rely on third-party summaries.
  2. Focus on application, not just facts. Choose courses with case studies. Look for ones that ask you to make decisions, not just recall numbers.
  3. Use the FDA Orange Book monthly. Bookmark it. Check for updates on drugs you commonly dispense. Set a calendar reminder to review it every first of the month.
  4. Join a peer group. Many hospital pharmacies now have monthly case review sessions focused on generics. If yours doesn’t, start one.
  5. Track your own errors. If you’ve ever second-guessed a substitution, write it down. Turn it into a learning moment.

On average, pharmacists spend 27.5 hours a year on CE. Only 5.2 of those are spent on generics and therapeutics. That’s not enough. If you’ve been in practice over 10 years, you need 8-10 hours of targeted generics education annually. Newer pharmacists? At least 4-6. Don’t treat CE as a checkbox. Treat it as your safety net.

Tools and Resources That Actually Help

Here are a few trusted sources that deliver real value:

  • Pharmacist’s Letter - Offers free, ACPE-accredited modules on therapeutic equivalence, legal issues, and substitution ethics.
  • Wolters Kluwer - Covers USP Chapters 795, 797, and 800, critical for pharmacists handling compounded generics.
  • ASHP’s Online Learning Center - Has modules on biosimilars and complex generics, updated quarterly.
  • FDA Orange Book - The single most important resource. Download the mobile app.
  • PocketPrep - Mobile-friendly quizzes and flashcards built for busy pharmacists.

Don’t waste time on generic CE that feels like a chore. Pick the ones that make you better at your job. The goal isn’t to get a certificate-it’s to protect your patients.

Do all states require the same continuing education for generics?

No. While all 50 states require continuing education for license renewal, the topics, hours, and specific requirements vary. Some states mandate training on biosimilars, narrow therapeutic index drugs, or opioid alternatives. Illinois requires Sexual Harassment Prevention and Implicit Bias training. New York requires submission of CE certificates with renewal. Always check your state board’s official website for the most current rules.

What is the FDA Orange Book and why does it matter?

The FDA Orange Book is the official publication listing approved drug products with therapeutic equivalence evaluations. It tells pharmacists which generics are rated as AB (therapeutically equivalent) to brand-name drugs and which are not. Substituting a non-equivalent generic can lead to treatment failure or adverse effects, especially with drugs like levothyroxine, warfarin, or phenytoin. Pharmacists must check the Orange Book regularly-updates happen monthly.

Are biosimilars the same as generics?

No. Biosimilars are complex biologic drugs that are highly similar to an approved biologic (like Humira or Enbrel), but not identical. Unlike traditional generics, which are chemically identical to their brand counterparts, biosimilars are made from living cells and have slight structural differences. Interchangeability must be specifically approved by the FDA, and pharmacists must understand when substitution is allowed and when it requires prescriber authorization.

How many hours of CE do I need for generics?

There’s no universal number-it depends on your state. But experts recommend at least 4-6 hours per year for newer pharmacists and 8-10 hours for those with 10+ years of experience. The average pharmacist spends only 5.2 hours annually on generics-specific education, which is below what’s needed to stay current given the rapid pace of change.

Can I get free continuing education on generics?

Yes. Pharmacist’s Letter offers free, ACPE-accredited CE modules on therapeutic equivalence, legal issues, and substitution ethics. Other providers like ASHP and Wolters Kluwer also offer free or low-cost content. Always verify the course is ACPE-accredited or approved by your state board before completing it for credit.

What happens if I don’t complete my CE requirements?

Failing to complete required continuing education can result in license suspension or non-renewal. Some states allow a grace period with a late fee, but others impose stricter penalties, including mandatory remediation or re-examination. More importantly, skipping education puts patients at risk. Generics errors are preventable-and staying current is part of your professional responsibility.

Comments (10)

Joni O

i just switched my ce provider last month and holy crap, the case studies actually stuck. i used to zone out during videos, but now i’m taking notes like i’m in a real pharmacy. 4 hours on levothyroxine bioequivalence and i caught a wrong substitution before it happened. thank god for application-based learning.

Selina Warren

you think this is about ce? no. this is about pharmacists being treated like glorified cashiers while the system lets generics flood in without real oversight. the FDA’s 80-125% window is a joke. if your thyroid med varies that much, you’re not getting medicine-you’re getting russian roulette. and don’t get me started on how brand companies block testing. this isn’t regulation-it’s corporate sabotage, and we’re the ones getting blamed when patients crash.

Robert Davis

the orange book is outdated. i’ve seen cases where the rating changed on the 15th, but the pharmacy system still shows the old one because the vendor hasn’t updated their database. i’ve reported it three times. no one cares. they’d rather you just click ‘confirm substitution’ and move on. this isn’t negligence-it’s systemic abandonment.

Jake Moore

if you’re not checking the orange book monthly, you’re gambling. i started setting a calendar reminder for the 1st of every month. last month, i caught two generics that dropped from AB to BN. one was for a patient on warfarin. i called the prescriber before filling. saved a potential bleed. this isn’t busywork-it’s your job.

Praseetha Pn

they’re lying to us. the FDA approves generics with zero clinical trials-just bioequivalence. but what if the patient is elderly? diabetic? renal failure? those variables aren’t in the lab reports. and the ‘interchangeable’ label? that’s a marketing term. i’ve seen biosimilars cause anaphylaxis because the excipients changed. nobody talks about this. why? because the pharma lobby owns the board. you think your ce credits matter? they’re just distractions while they poison the well.

Ryan Otto

the entire generics framework is a statistical illusion. the 90% adoption rate is not a triumph-it is a symptom of cost-driven medical collapse. the FDA’s therapeutic equivalence ratings are based on healthy adult males in controlled environments. real patients are not lab rats. the fact that pharmacists are expected to navigate this minefield with quarterly CE updates is not professional development-it is institutionalized malpractice. The CREATES Act? A PR stunt. The real issue? Capitalism has no place in pharmacology.

Nishant Sonuley

look, i get it-ce feels like a chore until you realize it’s the only thing standing between you and a lawsuit. i used to roll my eyes at case studies, but then i had a guy come back with a TSH of 120 after a switch from one generic to another. turned out the new one was BN-rated, and the old system didn’t flag it. now i do a quick orange book check before every high-risk med. it takes 90 seconds. i’ve saved two people this year. and honestly? it’s the only part of my job that still feels meaningful.

Emma #########

just wanted to say thank you for this. i’m a new grad and i’ve been terrified of making a mistake with generics. this post gave me a roadmap-not just rules, but real ways to stay safe. i printed the list of resources and taped it to my locker. i’m not alone in this.

Eric Gebeke

you’re all missing the point. the real problem isn’t the CE or the orange book-it’s that pharmacists have been trained to be silent. we’re not supposed to question substitutions. we’re supposed to fill and forget. and when someone dies? it’s ‘human error.’ never mind that the system set them up to fail. the industry doesn’t want you to learn-it wants you to comply. and if you’re not angry about that, you’re not paying attention.

Andrew McLarren

the assertion that continuing education is a safety net is both accurate and profoundly undersold. the pharmacopeia is not static; it is a dynamic, evolving ecosystem governed by scientific, regulatory, and commercial forces. to neglect ongoing education is not merely professional negligence-it is an ethical breach of the fiduciary duty owed to the patient. i commend the author for framing this not as a regulatory burden, but as a moral imperative. may we all strive to meet that standard with diligence and integrity.

Write a comment

about author

Angus Williams

Angus Williams

I am a pharmaceutical expert with a profound interest in the intersection of medication and modern treatments. I spend my days researching the latest developments in the field to ensure that my work remains relevant and impactful. In addition, I enjoy writing articles exploring new supplements and their potential benefits. My goal is to help people make informed choices about their health through better understanding of available treatments.

our related post

related Blogs

Ventolin Inhaler (Albuterol) vs. Top Alternatives - Detailed Comparison

Ventolin Inhaler (Albuterol) vs. Top Alternatives - Detailed Comparison

A detailed comparison of Ventolin inhaler (albuterol) versus popular alternatives, covering effectiveness, device types, pricing, and how to choose the right rescue inhaler for you.

Read More
SGLT2 Inhibitors and Diabetic Ketoacidosis: What You Need to Know About the Hidden Risk

SGLT2 Inhibitors and Diabetic Ketoacidosis: What You Need to Know About the Hidden Risk

SGLT2 inhibitors help manage type 2 diabetes but carry a hidden risk of euglycemic diabetic ketoacidosis-a dangerous condition that can occur even with normal blood sugar. Learn the signs, who’s at risk, and how to stay safe.

Read More
Blood Clot Prevention Protocols in the OR: Strategies, Facts & Expert Tips

Blood Clot Prevention Protocols in the OR: Strategies, Facts & Expert Tips

Explore practical blood clot prevention protocols used by anesthesiologists in the OR, including effective mechanical and pharmacologic methods and essential tips for safety.

Read More